How do breakthroughs in the lab become real-world treatments that save lives? In this episode, Professor Stephen Maher of Trinity College Dublin joins us to discuss the rapidly evolving field of translational oncology and how cutting-edge research is shaping the future of cancer therapy.

As a leading expert in radiation research and Director of Postgraduate Studies for the School of Medicine at Trinity, Stephen focuses on a critical question: why do some cancers respond to treatment while others resist it? His work examines the role of microRNAs, tumor hypoxia, and DNA damage response in shaping how cancers react to chemotherapy and radiotherapy — with particular attention to oesophageal and pancreatic cancers.

In this episode, we explore:

• Where anti-cancer therapeutics are headed in the coming years
• How radiation research is evolving to improve treatment precision
• Why translational oncology is essential for turning discovery into patient care
• How treatment resistance forms — and what researchers are doing to overcome it

After earning his Ph.D. in Oncology at RCSI and completing a fellowship at the National Cancer Institute in Maryland, Professor Maher has dedicated his career to bridging the gap between scientific discovery and clinical impact. He leads major national and international collaborations and has helped build advanced radiotherapy and hypoxia research programs at Trinity’s Translational Medicine Institute.

Learn more about Professor Maher and his work here.

Episode also available on Apple Podcasts: https://apple.co/38oMlMr

🛍️ Recommended Products & Reads from This Episode:

• 🎙️ Blue Yeti USB Microphone – A top choice for aspiring podcasters and speakers who want professional-grade audio at home.
  👉Check it out

Note: These are affiliate links. If you make a purchase through them, we may earn a small commission at no extra cost to you. It helps support the podcast. Thank you!

Podcast: Play in new window | Download | Embed